Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-11-23 Legal Proceedings Report
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2018年第二次临时股东大会之法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedures, attendance, and voting results of the 2018 second extraordinary general meeting (临时股东大会) of Harbin Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting's convening, attendance, voting procedures, and results. The document does not contain financial statements or management discussion but focuses on the legal validation of the shareholder meeting and its resolutions. It is not an announcement of voting results per se, but a legal opinion on the meeting's conduct and results. Given the nature of the document as a legal opinion on a shareholder meeting, it fits best under Legal Proceedings Report (LTR) rather than Declaration of Voting Results (DVA) or Regulatory Filings (RNS). The document length is under 5,000 characters, but it is a substantive legal opinion, not a mere announcement. Therefore, the classification is LTR with high confidence.
2018-11-23 Chinese
2018年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2018 second extraordinary general meeting of shareholders of 哈药集团股份有限公司. It details the meeting date, attendance, voting results, and legal witness statements. It does not contain financial statements or detailed financial analysis, but rather the official voting results and procedural compliance information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2018-11-23 Chinese
关于控股股东哈药集团重启混改事宜的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a mixed-ownership reform (混改) by the controlling shareholder of the company. It includes details about an asset valuation report, government approvals, and risk warnings related to the reform process. The document is relatively short (854 characters) and serves as a progress update rather than a full financial report or detailed presentation. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it provides substantive update information. The content fits best under a general regulatory announcement category about corporate developments and disclosures. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-11-23 Chinese
八届十五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. regarding the unlocking of restricted stock incentive plan shares. It details the board meeting, voting results, and authorization related to the stock incentive plan. There is no financial report, earnings data, or regulatory certification. The content focuses on a board decision about stock incentives, which is a management/board information update rather than a financial report or announcement of voting results. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS.
2018-11-23 Chinese
独立董事关于公司首期限制性股票激励计划首次授予第一个解锁期解锁的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent opinion from the independent directors of 哈药集团股份有限公司 regarding the first unlocking period of a restricted stock incentive plan. It references compliance with relevant laws and regulations, the number of shares unlocked, and the legitimacy of the unlocking process. The document is a formal statement or opinion on a specific corporate action related to stock incentives, not a full financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. This type of document fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure related to corporate governance and stock incentive plans but does not match other more specific categories like Remuneration Information or Share Issue/Capital Change since it is an independent opinion rather than an announcement of a capital change or remuneration report.
2018-11-23 Chinese
八届七次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 哈药集团股份有限公司 regarding the unlocking of restricted stock under a stock incentive plan. It is a formal announcement of a board decision, not a full report or financial statement. The document is short (614 characters) and contains no financial data or detailed analysis. It is not an annual report, interim report, or earnings release. It is not a proxy solicitation or voting result announcement. It is a board/management related announcement about a stock incentive plan approval. Therefore, the most appropriate classification is Board/Management Information (MANG).
2018-11-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.